HeartMate 3 用于左心室辅助装置更换的早期结局
单中心回顾性研究比较19例更换为HeartMate 3(HM3)与85例更换为HeartMate II或HeartWare的患者,HM3组虽合并更高BMI和更多既往手术,但无术后不良事件率差异,且免于死亡或再次更换的复合终点显著更优(P=.039),随访无血栓事件。
要点
- HM3更换组免于死亡或再次更换的复合终点显著优于对照组(P=.039)。
- HM3组术后不良事件率与对照组无差异,随访无血栓事件。
- HM3组BMI更高、既往LVAD植入和胸骨切开次数更多,仍安全可行。
核心结论
- HM3作为左心室辅助装置更换泵安全可行,可能为需要更换LVAD患者的首选泵。
研究设计与样本
- 单中心回顾性研究,2010年1月至2018年8月连续19例更换为HM3(组1)与85例更换为HeartMate II或HeartWare(组2)对照。
主要发现
- HM3组BMI显著更高(37 vs 31.6,P=.01)。
- HM3组有2次既往LVAD植入者比例更高(36.8% vs 5.9%,P<.001)。
- HM3组有3次既往胸骨切开者比例更高(31.6% vs 7.1%,P=.001)。
- 两组术后不良事件率无差异。
- HM3组免于死亡或再次更换的复合终点显著更优(P=.039),随访无血栓事件。
临床怎么用
- 对需要更换耐久性LVAD且合并装置相关并发症的患者,可考虑选用HM3作为更换泵。
局限性
- 单中心回顾性设计,样本量小(HM3组19例),组间基线特征存在差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The HeartMate 3 (HM3) left ventricular assist device (LVAD) (Abbott, Inc, Chicago, Ill) is a fully magnetically levitated centrifugal implantable pump used to treat patients with chronic heart failure. The MOMENTUM (Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3) trial demonstrated that patients treated with the HM3 experienced reduced need for reoperation for LVAD replacement compared with a control group receiving an axial flow design, Heartmate II (Abbott, Inc). However, there are few reports of using HM3 as the replacement pump in patients who already are supported by a durable LVAD and experience a device-related complication necessitating replacement. METHODS: An institutional LVAD database was used to identify 19 consecutive patients who underwent pump replacement to HM3 (group 1) versus 85 consecutive control patients who underwent pump replacement to either Heartmate II or HeartWare Ventricular Assist Device (Medtronic Inc, Minneapolis, Minn) (group 2), at a single institution from January 2010 to August 2018. Patient baseline characteristic and outcomes were obtained from a prospectively maintained database. The primary endpoint was a composite of freedom from death or need for another replacement surgery. RESULTS: There was no difference between the groups in heart failure etiology, indication for replacement, as well as the average days on the previous pump or the type of previous pump. The HM3 group did have a significantly greater body mass index (37 vs 31.6 P = .01), a greater number of previous LVAD implants (36.8% vs 5.9%, had 2 previous LVADs, P < .001), and a greater number of previous sternotomies (31.6% vs 7.1%, had 3 previous sternotomies, P = .001). No difference was found between the groups in terms of postoperative adverse event rates. With regards to the primary endpoint, the patients with HM3 replacements (group 1) versus group 2 experienced significantly greater freedom from either death or need for another replacement during the follow-up period (P = .039). During follow-up, there were no thrombosis events for the patients who received replacement with HM3. CONCLUSIONS: LVAD replacement with HM3 can be performed safely and may be considered as the pump of choice in patients requiring LVAD replacement.
引用
- Barac YD, Wojnarski CM, Junpaparp P, et al. Early outcomes with durable left ventricular assist device replacement using the HeartMate 3. J Thorac Cardiovasc Surg. 2019. PMID: 31740114. doi:10.1016/j.jtcvs.2019.09.151
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。